Audit of the use of drotrecogin alfa (activated) for severe sepsis (Xigris)



ТО	Emma North	FROM	
	Research Administrator, ICNARC	Name:	
Fax Number:	020 7388 3759	Hospital:	
ADMISSION		Today's date:	
CMP Admission Number: Date of admission to your unit:			
INFUSION			
Date of first infusion of Xigris:			
Did the patient receive the complete 96-hour infusion of Xigris? Yes No			
If No , please state why not:			
			, <u> </u>
Was there any interruption in the infusion of Xigris?			
If Yes, on what date and at what time did the interruption occur? Date: Time: Time:			
What was the duration of the interruption? (hours:mins)			
What was the reason for the interruption in the infusion?			
Was this infusion given as part of a study/trial? Yes No Name of study/trial?			
INFECTION			
Do you know the primary site of this patient's infection?			
If Yes , please indicate the site: Lung: Abdomen: Urinary tract: Other:			
If Other , please state site:			
Was a blood culture done prior to the infusion of Xigris? Yes No No Hes, was it positive? Yes No			
Was an organism cultured for this patient's infection?			
If Yes , please tick <u>all</u> organisms cultured:			
Gram-negative bacteria Gram-positive bacteria Fungus			
Name of primary pathogen (or state if not known)			
ADVERSE EVENTS			
Did a serious adverse event occur (any adverse event assessed as serious by the clinician)?			
If Yes , was it a: Serious bleeding event §? Yes No Thrombotic event? Yes No Other event? Yes No			
If a serious bleeding event, please indicate site(s): If Other event, please state:			
Gastrointestinal ble	eed: Genitourinary bleed:	Skin or so	off tissue bleed:
Intrathoracic bleed	: Intraabdominal bleed:	Other (so	urce unidentified) bleed:
Intracranial bleed:	Retroperitoneal bleed:	Other (so	urce identified) bleed:
If Other (source identified) bleed, please state site(s):			

[§] Serious bleeding events are defined as any intracranial haemorrhage, any life-threatening bleed or any bleeding event requiring the administration of >= 3 units of packed red blood cells per day for two consecutive days, or any bleeding event assessed as serious by the clinician

© 2004

Intensive Care National Audit & Research Centre All rights reserved.